22 August 2025 in Cancer Letters
5 June 2026 in SSRN Electronic Journal
Background: The widespread occurrence of chronic obstructive pulmonary disease (COPD) significantly complicates the management of lung cancer (LC). Patients suffering from both LC and COPD generally have a poor prognosis and limited effectiveness from conventional therapies, yet they often respond well to immunotherapy. This study aims to characterize the unique tumor microenvironment (TME) of COPD-associated LC (COPD-LC) using multi-omics approaches and to elucidate the mechanisms influencing immunotherapy efficacy.Methods: We performed single‑cell RNA sequencing on tumor and adjacent normal tissues from 11 non‑small cell lung cancer patients (6 with COPD, 5 without), generating a single‑cell atlas of >200,000 cells. These data were integrated with spatial transcriptomics, mass spectrometry‑based proteomics, TCGA data mining, and functional in vitro experiments to systematically map the TME cellular landscape, cell‑cell interactions, and immune regulatory mechanisms in COPD-LC.Findings: Our research identified a distinct subset of CXCL12+ cancer-associated fibroblasts (CAFs) characterized by a heightened stromal signature. These specialized CAFs mediate immunosuppressive effects within the tumor microenvironment of LC patients with comorbid COPD through CXCL12-CXCR4 axis-mediated modulation of CD8+ T cell function. Spatial transcriptomics and multiplex immunofluorescence confirmed colocalization of CXCL12⁺ CAFs with CXCR4⁺ CD8⁺ T cells. SPP1⁺ tumor‑associated macrophages (TAMs) were significantly less abundant in COPD-LC compared to non‑COPD-LC, and this reduction was regulated by the hypoxia‑SPI1 signaling axis. SPP1⁺ TAMs promoted terminal exhaustion of CD8⁺ T cells, whereas in COPD patients CD8⁺ T cells remained in a more progenitor exhaustion state. In vitro assays demonstrated that CXCL12 reduced CD8⁺ T cell effector function (decreased TNF‑α, IFN‑γ, GZMB), while SPP1 upregulated exhaustion markers (PD‑1, TIM‑3) on CD8⁺ T cells.Interpretation: Our results highlight the specific characteristics of the TME that are linked to poor prognosis and altered sensitivity to immunotherapy in COPD-LC, offering a basis for prioritizing treatment strategies to improve therapeutic outcomes.